7 analysts have shared their evaluations of Keros Therapeutics (NASDAQ:KROS) during the recent three months, expressing a mix of bullish and bearish perspectives.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Analysts have recently evaluated Keros Therapeutics and provided 12-month price targets. The average target is $28.57, accompanied by a high estimate of $41.00 and a low estimate of $15.00. This current average represents a 35.27% decrease from the previous average price target of $44.14.

Understanding Analyst Ratings: A Comprehensive Breakdown

A clear picture of Keros Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Keros Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on Keros Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Keros Therapeutics: A Closer Look

Keros Therapeutics: Financial Performance Dissected

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Revenue Growth: Keros Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 2027.27%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1513.02%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Keros Therapeutics's ROE excels beyond industry benchmarks, reaching -8.34%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Keros Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.7% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: Keros Therapeutics's debt-to-equity ratio is below the industry average at 0.03, reflecting a lower dependency on debt financing and a more conservative financial approach.

How Are Analyst Ratings Determined?

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.